{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:10:15Z","timestamp":1783105815356,"version":"3.54.6"},"reference-count":31,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study investigates the role of donor-specific antibodies (DSAs) in liver transplantation outcomes, focusing on their effects on liver damage. Ninety-four patients who underwent liver transplantation between 2019 and 2024 at Atat\u00fcrk University were included. DSA testing was performed using the Luminex QIAGEN LifeCodes method. Patient demographic data, laboratory results, clinical conditions, and biopsy findings were analyzed. Disease-specific analyses were conducted for Wilson\u2019s disease, autoimmune hepatitis, hepatocellular carcinoma (HCC), and hepatitis B virus (HBV). Due to the limited sample size, larger validation studies are needed, and the impact of the COVID-19 pandemic on the data collection process was considered. At the end of 1 year, persistent DSA had no significant effect on liver damage. However, early DSA positivity, particularly persistence and titration, requires further investigation. In Wilson\u2019s disease, two DSA-positive patients (mean fluorescence intensity [MFI] 1,000\u20131,500) showed no damage. Among autoimmune hepatitis patients, 5 of 19 were DSA positive (MFI 1,700\u20135,600), with no detected damage. Four HCC patients were DSA positive (MFI 1,300\u20132,200). Among HBV patients, 12 of 31 were DSA positive, and 5 experienced liver damage. Tacrolimus levels in the third month were statistically associated with bilirubin levels. Prospective studies are needed to further clarify the clinical significance of DSA.<\/jats:p>","DOI":"10.1515\/biol-2025-1078","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T01:45:34Z","timestamp":1742607934000},"source":"Crossref","is-referenced-by-count":2,"title":["Effects of\n                    <i>de novo<\/i>\n                    donor-specific Class I and II antibodies on graft outcomes after liver transplantation: A pilot cohort study"],"prefix":"10.1515","volume":"20","author":[{"given":"Necip","family":"Altunda\u015f","sequence":"first","affiliation":[{"name":"Department of General Surgery, Atat\u00fcrk University , 25240 , Erzurum , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eda","family":"Balkan","sequence":"additional","affiliation":[{"name":"Department of Medical Biology, Faculty of Medicine, Atat\u00fcrk University , 21 Lalapa\u015fa , 25240 , Erzurum , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Kizilkaya","sequence":"additional","affiliation":[{"name":"Department of Medical Biology, Faculty of Medicine, Atat\u00fcrk University , 21 Lalapa\u015fa , 25240 , Erzurum , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurhak","family":"Aksungur","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Atat\u00fcrk University , 25240 , Erzurum , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salih","family":"Kara","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Atat\u00fcrk University , 25240 , Erzurum , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Demirci","sequence":"additional","affiliation":[{"name":"Department of Pathology, Atat\u00fcrk University , 25240 , Erzurum , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ercan","family":"Korkut","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Atat\u00fcrk University , 25240 , Erzurum , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcrkan","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Atat\u00fcrk University , 25240 , Erzurum , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Dursun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Atat\u00fcrk University , 25240 , Erzurum , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"key":"2025122123391900996_j_biol-2025-1078_ref_001","doi-asserted-by":"crossref","unstructured":"Uebayashi EY, Okajima H, Yamamoto M, Ogawa E, Okamoto T, Haga H, et al. The new challenge in pediatric liver transplantation: Chronic antibody-mediated rejection. J Clin Med. 2022 Aug;11(16):2\u201310. [cited 2024 Aug 26] https:\/\/pubmed.ncbi.nlm.nih.gov\/36013073\/.","DOI":"10.3390\/jcm11164834"},{"key":"2025122123391900996_j_biol-2025-1078_ref_002","doi-asserted-by":"crossref","unstructured":"O\u2019Leary JG, Cai J, Freeman R, Banuelos N, Hart B, Johnson M, et al. Proposed diagnostic criteria for chronic antibody-mediated rejection in liver allografts. Am J Transplantant. 2016 Feb;16(2):603\u201314.","DOI":"10.1111\/ajt.13476"},{"key":"2025122123391900996_j_biol-2025-1078_ref_003","doi-asserted-by":"crossref","unstructured":"Feng S, Bucuvalas JC, Demetris AJ, Burrell BE, Spain KM, Kanaparthi S, et al. Evidence of chronic allograft injury in liver biopsies from long-term pediatric recipients of liver transplants. Gastroenterology. 2018 Dec;155(6):1838. [cited 2024 Aug 26] \/pmc\/articles\/PMC6279538\/.","DOI":"10.1053\/j.gastro.2018.08.023"},{"key":"2025122123391900996_j_biol-2025-1078_ref_004","doi-asserted-by":"crossref","unstructured":"Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, Egawa H, Yurugi K, Masuda S, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl. 2012 Nov;18(11):1333\u201342. [cited 2024 Aug 26] https:\/\/pubmed.ncbi.nlm.nih.gov\/22888064\/.","DOI":"10.1002\/lt.23534"},{"key":"2025122123391900996_j_biol-2025-1078_ref_005","doi-asserted-by":"crossref","unstructured":"Wozniak LJ, Hickey MJ, Venick RS, Vargas JH, Farmer DG, Busuttil RW, et al. Donor-specific HLA antibodies are associated with late allograft dysfunction after pediatric liver transplantation. Transplantation. 2015 Jul;99(7):1416\u201322. [cited 2024 Aug 26] https:\/\/pubmed.ncbi.nlm.nih.gov\/26038872\/.","DOI":"10.1097\/TP.0000000000000796"},{"key":"2025122123391900996_j_biol-2025-1078_ref_006","doi-asserted-by":"crossref","unstructured":"Loupy A, Lefaucheur C. Antibody-mediated rejection of solid-organ allografts. N Engl J Med. 2018 Sep;379(12):1150\u201360. [cited 2024 Aug 26] https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMra1802677.","DOI":"10.1056\/NEJMra1802677"},{"key":"2025122123391900996_j_biol-2025-1078_ref_007","doi-asserted-by":"crossref","unstructured":"Montgomery RA, Tatapudi VS, Leffell MS, Zachary AA. HLA in transplantation. Nat Rev Nephrol. 2018 Sep;14(9):558\u201370. [cited 2024 Aug 26] https:\/\/pure.johnshopkins.edu\/en\/publications\/hla-in-transplantation.","DOI":"10.1038\/s41581-018-0039-x"},{"key":"2025122123391900996_j_biol-2025-1078_ref_008","doi-asserted-by":"crossref","unstructured":"Lefaucheur C, Louis K, Morris AB, Taupin JL, Nickerson P, Tambur AR, et al. Clinical recommendations for posttransplant assessment of anti\u2013HLA (Human Leukocyte Antigen) donor-specific antibodies: A sensitization in transplantation: Assessment of risk consensus document. Am J Transplant. 2023 Jan;23(1):115\u201332.","DOI":"10.1016\/j.ajt.2022.11.013"},{"key":"2025122123391900996_j_biol-2025-1078_ref_009","doi-asserted-by":"crossref","unstructured":"Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transpl. 2018 Feb;18(2):293\u2013307. [cited 2024 Aug 26] https:\/\/pubmed.ncbi.nlm.nih.gov\/29243394\/.","DOI":"10.1111\/ajt.14625"},{"key":"2025122123391900996_j_biol-2025-1078_ref_010","doi-asserted-by":"crossref","unstructured":"Tambur AR, Campbell P, Chong AS, Feng S, Ford ML, Gebel H, et al. Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report. Am J Transplant. 2020 Oct;20(10):2652\u201368. [cited 2024 Aug 26] https:\/\/pubmed.ncbi.nlm.nih.gov\/32342639\/.","DOI":"10.1111\/ajt.15937"},{"key":"2025122123391900996_j_biol-2025-1078_ref_011","doi-asserted-by":"crossref","unstructured":"Smith AG, Pereira S, Jaramillo A, Stoll ST, Khan FM, Berka N, et al. Comparison of sequence-specific oligonucleotide probe vs next generation sequencing for HLA-A, B, C, DRB1, DRB3\/B4\/B5, DQA1, DQB1, DPA1, and DPB1 typing: Toward single-pass high-resolution HLA typing in support of solid organ and hematopoietic cell transplant programs. HLA. 2019;94(3):296\u2013306. [cited 2024 Sep 4] https:\/\/pubmed.ncbi.nlm.nih.gov\/31237117\/.","DOI":"10.1111\/tan.13619"},{"key":"2025122123391900996_j_biol-2025-1078_ref_012","doi-asserted-by":"crossref","unstructured":"Senev A, Emonds MP, Van Sandt V, Lerut E, Coemans M, Sprangers B, et al. Clinical importance of extended second field high-resolution HLA genotyping for kidney transplantation. Am J Transplant. 2020 Dec;20(12):3367\u201378. [cited 2024 Sep 4] https:\/\/pubmed.ncbi.nlm.nih.gov\/32337773\/.","DOI":"10.1111\/ajt.15938"},{"key":"2025122123391900996_j_biol-2025-1078_ref_013","doi-asserted-by":"crossref","unstructured":"Huang Y, Dinh A, Heron S, Gasiewski A, Kneib C, Mehler H, et al. Assessing the utilization of high-resolution 2-field HLA typing in solid organ transplantation. Am J Transplant. 2019 Jul;19(7):1955\u201363. [cited 2024 Sep 4] https:\/\/pubmed.ncbi.nlm.nih.gov\/30623581\/.","DOI":"10.1111\/ajt.15258"},{"key":"2025122123391900996_j_biol-2025-1078_ref_014","doi-asserted-by":"crossref","unstructured":"Lefaucheur C, Louis K, Morris AB, Taupin JL, Nickerson P, Tambur AR, et al. Clinical recommendations for posttransplant assessment of anti-HLA (Human Leukocyte Antigen) donor-specific antibodies: A sensitization in transplantation: Assessment of risk consensus document. Am J Transplant. 2023 Jan;23(1):115\u201332. [cited 2024 Sep 4] https:\/\/pubmed.ncbi.nlm.nih.gov\/36695614\/.","DOI":"10.1016\/j.ajt.2022.11.013"},{"key":"2025122123391900996_j_biol-2025-1078_ref_015","doi-asserted-by":"crossref","unstructured":"Taner T, Gandhi MJ, Sanderson SO, Poterucha CR, De Goey SR, Stegall MD, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant. 2012 Jun;12(6):1504\u201310. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/22420671\/.","DOI":"10.1111\/j.1600-6143.2012.03995.x"},{"key":"2025122123391900996_j_biol-2025-1078_ref_016","doi-asserted-by":"crossref","unstructured":"Vandevoorde K, Ducreux S, Bosch A, Guillaud O, Hervieu V, Chambon-Augoyard C, et al. Prevalence, risk factors, and impact of donor-specific alloantibodies after adult liver transplantation. Liver Transplant. 2018 Aug;24(8):1091\u2013100. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/29665189\/.","DOI":"10.1002\/lt.25177"},{"key":"2025122123391900996_j_biol-2025-1078_ref_017","doi-asserted-by":"crossref","unstructured":"O\u2019Leary JG, Kaneku H, Jennings LW, Ba\u00f1uelos N, Susskind BM, Terasaki PI, et al. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transplant. 2013 Sep;19(9):973\u201380. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/23780820\/.","DOI":"10.1002\/lt.23687"},{"key":"2025122123391900996_j_biol-2025-1078_ref_018","doi-asserted-by":"crossref","unstructured":"Kaneku H, O\u2019Leary JG, Banuelos N, Jennings LW, Susskind BM, Klintmalm GB, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant. 2013 Apr;13(6):1541\u20138. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/23721554\/.","DOI":"10.1111\/ajt.12212"},{"key":"2025122123391900996_j_biol-2025-1078_ref_019","doi-asserted-by":"crossref","unstructured":"Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssi\u00e8re L, Esposito L, et al. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. Transplant Int. 2015 Dec;28(12):1371\u201382. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/26303035\/.","DOI":"10.1111\/tri.12654"},{"key":"2025122123391900996_j_biol-2025-1078_ref_020","doi-asserted-by":"crossref","unstructured":"Del Bello A, Congy-Jolivet N, Muscari F, Lavayssi\u00e8re L, Esposito L, Cardeau-Desangles I, et al. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant. 2014;14(4):867\u201375. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/24580771\/.","DOI":"10.1111\/ajt.12651"},{"key":"2025122123391900996_j_biol-2025-1078_ref_021","doi-asserted-by":"crossref","unstructured":"O\u2019Leary JG, Kaneku H, Jennings L, Susskind BM, Terasaki PI, Klintmalm GB. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. Liver Transplant. 2014;20(6):655\u201363. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/24678017\/.","DOI":"10.1002\/lt.23854"},{"key":"2025122123391900996_j_biol-2025-1078_ref_022","doi-asserted-by":"crossref","unstructured":"Ducreux S, Guillaud O, Bosch A, Thaunat O, Morelon E, Hervieu V, et al. Monitoring efficiency of humoral rejection episode therapy in liver transplantation: Any role for complement binding Luminex Single Antigen assays? Transplant Immunol. 2016 Mar;35:23\u20138. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/26845020\/.","DOI":"10.1016\/j.trim.2016.01.007"},{"key":"2025122123391900996_j_biol-2025-1078_ref_023","unstructured":"Marcos AC, Ruiz RD, Crist\u00f3bal MR, Yunquera AF, D\u00edaz-Fontenla F, Carazo LP, et al. Long-term outcomes and clinical impact of anti-HLA donor-specific antibodies (DSA) after liver transplantation: a prospective study in a pilot cohort. Rev Esp Enferm Dig. 2021 Aug;113(8):557\u201362. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/33244987\/."},{"key":"2025122123391900996_j_biol-2025-1078_ref_024","doi-asserted-by":"crossref","unstructured":"Liu W, Wang K, Xiao YL, Liu C, Gao W, Li DH. Clinical relevance of donor-specific human leukocyte antigen antibodies after pediatric liver transplantation. Exp Ther Med. 2021 Jun;22(2):1\u20137. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/34194545\/.","DOI":"10.3892\/etm.2021.10299"},{"key":"2025122123391900996_j_biol-2025-1078_ref_025","doi-asserted-by":"crossref","unstructured":"Kovandova B, Slavcev A, Honsova E, Erhartova D, Skibova J, Viklicky O, et al. De novo HLA Class II antibodies are associated with the development of chronic but not acute antibody-mediated rejection after liver transplantation \u2013 a retrospective study. Transplant Int. 2020 Dec;33(12):1799\u2013806. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/33020979\/.","DOI":"10.1111\/tri.13763"},{"key":"2025122123391900996_j_biol-2025-1078_ref_026","doi-asserted-by":"crossref","unstructured":"Beyzaei Z, Geramizadeh B, Bagheri Z, Karimzadeh S, Shojazadeh A. De novo donor specific antibody and long-term outcome after liver transplantation: A systematic review and meta-analysis. Front Immunol. 2020 Dec;11:1\u201311. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/33424868\/.","DOI":"10.3389\/fimmu.2020.613128"},{"key":"2025122123391900996_j_biol-2025-1078_ref_027","doi-asserted-by":"crossref","unstructured":"Jucaud V, Shaked A, DesMarais M, Sayre P, Feng S, Levitsky J, et al. Prevalence and impact of De novo donor-specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients. Hepatology. 2019 Mar;69(3):1273\u201386. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/30229989\/.","DOI":"10.1002\/hep.30281"},{"key":"2025122123391900996_j_biol-2025-1078_ref_028","doi-asserted-by":"crossref","unstructured":"Pinon M, Pizzol A, Chiad\u00f2 C, David E, Chiusa L, Dell\u2019Olio D, et al. Evaluation of graft fibrosis, inflammation, and donor-specific antibodies at protocol liver biopsies in pediatric liver transplant patients: A single-center experience. Transplantation. 2022 Jan;106(1):85\u201395. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/33496554\/.","DOI":"10.1097\/TP.0000000000003649"},{"key":"2025122123391900996_j_biol-2025-1078_ref_029","doi-asserted-by":"crossref","unstructured":"Kim PTW, Demetris AJ, O\u2019Leary JG. Prevention and treatment of liver allograft antibody-mediated rejection and the role of the \u201ctwo-hit hypothesis\u201d. Curr Opin Organ Transplant. 2016 Apr;21(2):209\u201318. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/26918881\/.","DOI":"10.1097\/MOT.0000000000000275"},{"key":"2025122123391900996_j_biol-2025-1078_ref_030","doi-asserted-by":"crossref","unstructured":"Feng S, Bucuvalas JC, Demetris AJ, Burrell BE, Spain KM, Kanaparthi S, et al. Evidence of chronic allograft injury in liver biopsies from long-term pediatric recipients of liver transplants. Gastroenterology. 2018 Dec;155(6):1838\u201351.e7. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/30144432\/.","DOI":"10.1053\/j.gastro.2018.08.023"},{"key":"2025122123391900996_j_biol-2025-1078_ref_031","doi-asserted-by":"crossref","unstructured":"O\u2019Leary JG, Shiller SM, Bellamy C, Nalesnik MA, Kaneku H, Jennings LW, et al. Acute liver allograft antibody-mediated rejection: An inter-institutional study of significant histopathological features. Liver Transplant. 2014 Oct;20(10):1244\u201355. [cited 2024 Sep 3] https:\/\/pubmed.ncbi.nlm.nih.gov\/25045154\/.","DOI":"10.1002\/lt.23948"}],"container-title":["Open Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/biol-2025-1078\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/biol-2025-1078\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T23:39:42Z","timestamp":1766360382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/biol-2025-1078\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3,7]]},"published-print":{"date-parts":[[2025,3,7]]}},"alternative-id":["10.1515\/biol-2025-1078"],"URL":"https:\/\/doi.org\/10.1515\/biol-2025-1078","relation":{},"ISSN":["2391-5412"],"issn-type":[{"value":"2391-5412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]},"article-number":"20251078"}}